. 2020 Mar 28;9(1):16–23. doi: 10.4103/jrpp.JRPP_19_110

Table 3.

Different hemoglobin A1c levels (>7%, >8% and>9%) pre- and post-direct acting antiviral treatment*

HbA1c levels	Study groups	Mean HbA1c (%)±SD		Mean change in HbA1c±SD	Mean difference between groups	P*
HbA1c levels	Study groups	Pre-index Prior DAA treatment	Post-index After DAA treatment	Mean change in HbA1c±SD	Mean difference between groups	P*
>7% (n=570)	Achieved SVR (n=540)	8.4±1.25	7.7±1.28	0.76±1.35	−0.0654	0.7944^b
>7% (n=570)	Did not achieve SVR (n=30)	8.5±1.23	7.7±1.05	0.83±1.05	−0.0654	0.7944^b
>8% (n=309)	Achieved SVR (n=291)	9.3±1.17	8.0±1.50	1.23±1.52	−0.0442	0.9034^b
>8% (n=309)	Did not achieve SVR (n=18)	9.3±1.02	8.2+1.14	1.28±1.06	−0.0442	0.9034^b
>9% (n=140)	Achieved SVR (n=130)	10.2±1.17	8.4±1.81	1.83±1.78	0.4291	0.4562^b
>9% (n=140)	Did Not Achieve SVR (n=10)	10.1±0.69	8.7±1.29	1.40±1.29	0.4291	0.4562^b

*P<0.05 was defined as a statistically significant difference between the two groups. The following statistical test was used to calculate the P value: ^bWilcoxon test was used for continuous variables. Patients are not mutually exclusive since some patients could be in multiple categories. DAA=Direct-acting antiviral, HbA1c=Hemoglobin A1c, HCV=Hepatitis C virus, SVR=Sustained virologic response, SD=Standard deviation